Shahin MS - Search Results

1

Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Schilder RJ, Brady WE, Lankes HA, Fiorica JV, Shahin MS, Zhou XC, Mannel RS, Pathak HB, Hu W, Alpaugh RK, Sood AK, Godwin AK. Schilder RJ, et al. Among authors: shahin ms. Gynecol Oncol. 2012 Oct;127(1):70-4. doi: 10.1016/j.ygyno.2012.06.009. Epub 2012 Jun 16. Gynecol Oncol. 2012. PMID: 22710075 Free PMC article. Clinical Trial.

2

The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma.

Shahin MS, Hughes JH, Sood AK, Buller RE. Shahin MS, et al. Cancer. 2000 Nov 1;89(9):2006-17. doi: 10.1002/1097-0142(20001101)89:9<2006::aid-cncr18>3.3.co;2-z. Cancer. 2000. PMID: 11064359

3

p53 Mutations and microsatellite instability in ovarian cancer: Yin and yang.

Buller RE, Shahin MS, Holmes RW, Hatterman M, Kirby PA, Sood AK. Buller RE, et al. Among authors: shahin ms. Am J Obstet Gynecol. 2001 Apr;184(5):891-902; discussion 902-3. doi: 10.1067/mob.2001.113856. Am J Obstet Gynecol. 2001. PMID: 11303196

4

The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer.

Buller RE, Lallas TA, Shahin MS, Sood AK, Hatterman-Zogg M, Anderson B, Sorosky JI, Kirby PA. Buller RE, et al. Among authors: shahin ms. Clin Cancer Res. 2001 Apr;7(4):831-8. Clin Cancer Res. 2001. PMID: 11309330

5

Paclitaxel and platinum chemotherapy for ovarian carcinoma during pregnancy.

Sood AK, Shahin MS, Sorosky JI. Sood AK, et al. Among authors: shahin ms. Gynecol Oncol. 2001 Dec;83(3):599-600. doi: 10.1006/gyno.2001.6439. Gynecol Oncol. 2001. PMID: 11733979

6

Phase II evaluation of 3-day topotecan with cyclophosphamide in the treatment of recurrent ovarian cancer.

Hanjani P, Nolte S, Shahin MS. Hanjani P, et al. Among authors: shahin ms. Gynecol Oncol. 2002 May;85(2):278-84. doi: 10.1006/gyno.2002.6593. Gynecol Oncol. 2002. PMID: 11972388 Clinical Trial.

7

Anorectal dysfunction after surgical treatment for cervical cancer.

Sood AK, Nygaard I, Shahin MS, Sorosky JI, Lutgendorf SK, Rao SS. Sood AK, et al. Among authors: shahin ms. J Am Coll Surg. 2002 Oct;195(4):513-9. doi: 10.1016/s1072-7515(02)01311-x. J Am Coll Surg. 2002. PMID: 12375757

8

Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial.

Sood AK, Lush R, Geisler JP, Shahin MS, Sanders L, Sullivan D, Buller RE, Sorosky JI. Sood AK, et al. Among authors: shahin ms. Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6080-5. doi: 10.1158/1078-0432.CCR-04-0574. Clin Cancer Res. 2004. PMID: 15447993 Clinical Trial.

9

A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group study.

Rocereto TF, Brady WE, Shahin MS, Hoffman JS, Small L, Rotmensch J, Mannel RS. Rocereto TF, et al. Among authors: shahin ms. Gynecol Oncol. 2010 Mar;116(3):332-4. doi: 10.1016/j.ygyno.2009.10.071. Epub 2009 Nov 17. Gynecol Oncol. 2010. PMID: 19922989 Clinical Trial.

10

A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study.

Miller BE, Blessing JA, Stehman FB, Shahin MS, Yamada SD, Secord AA, Warshal DP, Abulafia O, Richards WE, Van Le L. Miller BE, et al. Among authors: shahin ms. Gynecol Oncol. 2010 Aug 1;118(2):139-44. doi: 10.1016/j.ygyno.2010.03.024. Epub 2010 May 8. Gynecol Oncol. 2010. PMID: 20452658 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

60 results

Search Page

Filters